⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29643735 | 1.00 | — | — | |
| SCHEMBL30844478 | 0.77 | TAAR1 (0.46) | — | |
| SCHEMBL15673033 | 0.77 | TAAR1 (0.46) | — | |
| SCHEMBL4932513 | 0.75 | MAPK14 (0.52) | — | |
| SCHEMBL3273312 | 0.74 | KMO (0.42) | — | |
| SCHEMBL17155347 | 0.73 | IDO1 (0.47) | — | |
| SCHEMBL172300 | 0.72 | — | — | |
| SCHEMBL4027001 | 0.72 | IDO1 (0.55) | — | |
| SCHEMBL31484870 | 0.72 | CCR1 (0.48) | — | |
| SCHEMBL1697620 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1069 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118388401-B | Preparation method of 4-amino-2-chloronicotinaldehyde | 成都凯斯坦生物医药有限公司 | 2024-08-20 | — | — | CN | claimed |
| CN-118388401-A | Preparation method of 4-amino-2-chloronicotinaldehyde | 成都凯斯坦生物医药有限公司 | 2024-07-26 | — | — | CN | claimed |
| CN-116836111-A | Continuous synthesis method of fluoropyridine | 峰成医药科技(天津)有限公司 | 2023-10-03 | — | — | CN | claimed |
| WO-2023174235-A1 | MUTANT IDH1 AND IDH2 INHIBITOR AND APPLICATION THEREOF | 贝达药业股份有限公司 | 2023-09-21 | — | — | WO | claimed |
| CN-102432592-A | Aryl urea derivative with anti-tumor effect and preparation method thereof | UNIV PEKING FOUNDER GROUP CO | 2012-05-02 | — | — | CN | claimed |
| CN-102408408-A | Aryl urea derivative with anti-tumor effect | UNIV PEKING FOUNDER GROUP CO | 2012-04-11 | — | — | CN | claimed |
| EP-4003988-B1 | 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | SERVIER LAB (FR) | 2026-05-20 | — | — | EP | disclosed |
| US-20260132139-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12617775-B2 | Processes of making CSF-1R inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2026-05-05 | — | — | US | disclosed |
| EP-4142732-B1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260102395-A1 | INHIBITING HISTONE DEACETYLASE 6 | EIKONIZO THERAPEUTICS, INC. (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260092063-A1 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | JAZZ PHARMACEUTICALS IRELAND LTD (IE) | 2026-04-02 | — | — | US | disclosed |
| EP-4178620-B1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1761518-A1 | NOVEL ALKYL SUBSTITUTED PIPERIDINE DERIVATIVES AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006094639-A1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-09-14 | — | — | WO | disclosed |
| US-20060199960-A1 | e.g. 6-Methyl-3-(pyridin-3-ylamino)-pyridine-2-carboxylic acid (4-methyl-thiazol-2-yl)-amide; metabotropic glutamate receptor antagonists (mGluR); central nervous system disorders, antidepressant, anxiolytc agent; psychosis, epilepsy, schizophrenia, Alzheimer's disease, cognitive disorders | HOFFMANN-LA ROCHE INC. | 2006-09-07 | — | — | US | disclosed |
| US-20060160857-A1 | Thiazole-4-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. | 2006-07-20 | — | — | US | disclosed |
| WO-2006074884-A1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-07-20 | — | — | WO | disclosed |
| WO-2005123715-A1 | NOVEL ALKYL SUBSTITUTED PIPERIDINE DERIVATIVES AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2005-12-29 | — | — | WO | disclosed |